This content is intended for UK & ROI healthcare professionals. Not a healthcare professional? Return to audience selector.

One size doesn’t fit all

Aqumeldi® is indicated for the treatment of heart failure in children from birth to less than 18 years1,2

Aqumeldi® is an innovative formulation and the first and only paediatric-licensed enalapril ODT for heart failure — because children are not just small adults3-5

Aqumeldi® is an innovative paediatric formulation — a mini ODT that rapidly disperses in the mouth3

Aqumeldi® is readily available in low dose strengths (0.25 mg & 1 mg) — enabling accurate titration and dose adjustments1,2,3

Aqumeldi® has dedicated paediatric clinical studies in HF establishing its safety profile over a duration of 1 year1,2,6

Use the links below to explore

Contact Form

Submit this form to contact the Proveca team. Please share the detail of any queries so we are able to direct your enquiry to the appropriate department.

References

  1.  Aqumeldi (0.25mg) Summary of Product Characteristics, (January 2024)
  2. Aqumeldi (1mg) Summary of Product Characteristics, (November 2025)
  3.  Bajcetic, M., et al., (2019). Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study Contemporary Clinical Trials Communications. Vol 15:100393
  4. Klassen, T.P., et al. (2008). Children are not just small adults: the urgent need for high quality trial evidence in children. PLOS Medicine. Vol 5(8):e172.
  5. British National Formulary for Children (BNFC). Enalapril maleate. Available from:https://bnfc.nice.org.uk/drugs/enalapril-maleate/  
  6. Data on file

UK-ENA-26-0001 | January 2026

Adverse Event Reporting Information

UK: Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. 

Republic of Ireland: Adverse events should be reported. Reporting forms and information can be found at: www.hpra.ie.

Adverse events should also be reported to Proveca Limited. Phone: +44 333 200 1866 E-Mail: medinfo@proveca.com

You are now leaving this website and will be redirected. Are you sure you wish to continue?

Continue